Franklin I Aigbirhio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2132971/publications.pdf

Version: 2024-02-01

65 papers

2,361 citations

257450 24 h-index 223800 46 g-index

80 all docs 80 docs citations

80 times ranked 3706 citing authors

#	Article	IF	CITATIONS
1	Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain, 2022, 145, 340-348.	7.6	21
2	InÂVivo ¹⁸ F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, 63, 1052-1057.	5.0	9
3	226†Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C]UCB-J PET. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A78.3-A78.	1.9	1
4	Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography. Neurobiology of Aging, 2021, 101, 172-180.	3.1	14
5	[18F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases. Brain Communications, 2021, 3, fcab177.	3.3	2
6	Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models. ACS Chemical Neuroscience, 2021, 12, 1885-1893.	3.5	8
7	Neuroinflammation predicts disease progression in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 769-775.	1.9	40
8	[11C]PK11195-PET Brain Imaging of the Mitochondrial Translocator Protein in Mitochondrial Disease. Neurology, 2021, 96, e2761-e2773.	1.1	7
9	In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiology of Aging, 2021, 101, 187-198.	3.1	17
10	Synaptic density in carriers of C9orf72 mutations: a [¹¹ C]UCB†PET study. Annals of Clinical and Translational Neurology, 2021, 8, 1515-1523.	3.7	27
11	Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 125-136.	6.4	11
12	Mapping the binding site topology of amyloid protein aggregates using multivalent ligands. Chemical Science, 2021, 12, 8892-8899.	7.4	6
13	Spatial and Temporal Pattern of Ischemia and Abnormal Vascular Function Following Traumatic Brain Injury. JAMA Neurology, 2020, 77, 339.	9.0	49
14	DJ-1 can form \hat{l}^2 -sheet structured aggregates that co-localize with pathological amyloid deposits. Neurobiology of Disease, 2020, 134, 104629.	4.4	13
15	Synaptic Loss in Primary Tauopathies Revealed by [<scp>¹¹C</scp>] <scp>UCBâ€J</scp> Positron Emission Tomography. Movement Disorders, 2020, 35, 1834-1842.	3.9	61
16	Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. Annals of Neurology, 2020, 88, 1194-1204.	5.3	38
17	Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain, 2020, 143, 1010-1026.	7.6	68
18	A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein. Chemical Science, 2020, 11, 4773-4778.	7.4	16

#	Article	IF	Citations
19	Automated radiosynthesis of [¹¹ C]UCBâ€J for imaging synaptic density by positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 151-158.	1.0	15
20	11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies. European Journal of Hybrid Imaging, 2020, 4, 25.	1.5	18
21	Insula serotonin 2A receptor binding and gene expression contribute to serotonin transporter polymorphism anxious phenotype in primates. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14761-14768.	7.1	20
22	Assessing the Effects of Cytoprotectants on Selective Neuronal Loss, Sensorimotor Deficit and Microglial Activation after Temporary Middle Cerebral Occlusion. Brain Sciences, 2019, 9, 287.	2.3	4
23	A simple and efficient automated cGMPâ€compliant radiosynthesis of [¹¹ C]metomidate using solid phase extraction cartridge purification. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 190-197.	1.0	4
24	Radiosynthesis of (<i>R</i> , <i>S</i>)â€{ ¹⁸ F]GE387: A Potential PET Radiotracer for Imaging Translocator Protein 18â€kDa (TSPO) with Low Binding Sensitivity to the Human Gene Polymorphism rs6971. ChemMedChem, 2019, 14, 982-993.	3.2	22
25	In vivo evidence for preâ€symptomatic neuroinflammation in a <scp>MAPT</scp> mutation carrier. Annals of Clinical and Translational Neurology, 2019, 6, 373-378.	3.7	27
26	Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics. ChemNanoMat, 2018, 4, 361-372.	2.8	13
27	[<i>Carboxyl</i> â€ ¹¹ C]Labelling of Four Highâ€Affinity cPLA2α Inhibitors and Their Evaluation as Radioligands in Mice by Positron Emission Tomography. ChemMedChem, 2018, 13, 138-146.	3.2	5
28	[¹⁸ F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1032-1037.	1.9	77
29	Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open, 2017, 7, e013187.	1.9	65
30	Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates Using Microscale Thermophoresis. ACS Chemical Neuroscience, 2017, 8, 2088-2095.	3.5	13
31	[ICâ€Pâ€155]: ESTABLISHMENT OF A PET RADIOTRACER NETWORK FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P117.	0.8	O
32	Effects of hyperoxia on 18F-fluoro-misonidazole brain uptake and tissue oxygen tension following middle cerebral artery occlusion in rodents: Pilot studies. PLoS ONE, 2017, 12, e0187087.	2.5	3
33	Targeted Molecular Imaging in Adrenal Diseaseâ€"An Emerging Role for Metomidate PET-CT. Diagnostics, 2016, 6, 42.	2.6	21
34	Hypoxia and tissue destruction in pulmonary TB. Thorax, 2016, 71, 1145-1153.	5.6	133
35	Radiosynthesis of Carbon-11 Labeled Puromycin as a Potential PET Candidate for Imaging Protein Synthesis <i>in Vivo</i> . ACS Medicinal Chemistry Letters, 2016, 7, 647-651.	2.8	4
36	Synthesis, in Vitro Evaluation, and Radiolabeling of Fluorinated Puromycin Analogues: Potential Candidates for PET Imaging of Protein Synthesis. Journal of Medicinal Chemistry, 2016, 59, 9422-9430.	6.4	23

#	Article	IF	CITATIONS
37	Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. European Journal of Endocrinology, 2016, 175, 485-498.	3.7	41
38	Pathophysiologic Mechanisms of Cerebral Ischemia and Diffusion Hypoxia in Traumatic Brain Injury. JAMA Neurology, 2016, 73, 542.	9.0	125
39	Dissociable Rate-Dependent Effects of Oral Methylphenidate on Impulsivity and D _{2/3} Receptor Availability in the Striatum. Journal of Neuroscience, 2015, 35, 3747-3755.	3.6	54
40	White Matter Perivascular Spaces on Magnetic Resonance Imaging. Stroke, 2015, 46, 1707-1709.	2.0	77
41	Synthesis and Initial <i>in Vivo</i> Studies with [¹¹ C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. ACS Medicinal Chemistry Letters, 2015, 6, 548-552.	2.8	38
42	An Efficient Method for Enhancing the Reactivity and Flexibility of [¹⁸ F]Fluoride Towards Nucleophilic Substitution Using Tetraethylammonium Bicarbonate. European Journal of Organic Chemistry, 2014, 2014, 6145-6149.	2.4	20
43	Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of Ï"-pathology. MedChemComm, 2013, 4, 852.	3.4	24
44	Characterizing infarction and selective neuronal loss following temporary focal cerebral ischemia in the rat: A multi-modality imaging study. Neurobiology of Disease, 2013, 51, 120-132.	4.4	38
45	A comparison of four PET tracers for brain hypoxia mapping in a rodent model of stroke. Nuclear Medicine and Biology, 2013, 40, 338-344.	0.6	15
46	A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain, 2013, 136, 3252-3270.	7.6	90
47	Is neural activation within the rescued penumbra impeded by selective neuronal loss?. Brain, 2013, 136, 1816-1829.	7.6	28
48	David James Silvester. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 338-339.	1.0	2
49	Evaluation of the Sensitivity and Specificity of $<$ sup $>$ 11 $<$ /sup $>$ C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 100-109.	3.6	203
50	Quantification of receptor–ligand binding potential in sub-striatal domains using probabilistic and template regions of interest. Neurolmage, 2011, 55, 101-112.	4.2	10
51	Single-subject statistical mapping of acute brain hypoxia in the rat following middle cerebral artery occlusion: A microPET study. Experimental Neurology, 2011, 229, 251-258.	4.1	17
52	Validation of reference tissue modelling for [11C]flumazenil positron emission tomography following head injury. Annals of Nuclear Medicine, 2011, 25, 396-405.	2.2	19
53	An automated method for regular productions of copper-64 for PET radiopharmaceuticals. Inorganica Chimica Acta, 2010, 363, 1316-1319.	2.4	19
54	Cellular confocal fluorescence studies and cytotoxic activity of new Zn(ii) bis(thiosemicarbazonato) complexes. Dalton Transactions, 2008, , 2107.	3.3	83

#	Article	IF	CITATIONS
55	In Vitro and In Vivo Evaluations of a Hydrophilic ⁶⁴ Cu-Bis(Thiosemicarbazonato)–Glucose Conjugate for Hypoxia Imaging. Journal of Nuclear Medicine, 2008, 49, 1862-1868. Comparison of Lorazepam	5.0	51
56	[7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] Occupancy of Rat Brain [3-Aminobutyric AcidA Receptors Measured Using in Vivo [3H]Flumazenil (8-Fluoro) Tj ETQq0 0 0 rgBT /Overloc and [11C]Flumazenil Micro-Positron Emission Tomography. Journal of Pharmacology and Experimental	k 10 _{2.5} 50	702 Jd (5,6-d
57	Therapeutics, 2007, 320, 1030-1037. Designing Zn(ii) and Cu(ii) derivatives as probes for in vitro fluorescence imaging. Dalton Transactions, 2007, , 4988.	3.3	72
58	Functionalized Bis(thiosemicarbazonato) Complexes of Zinc and Copper:Â Synthetic Platforms Toward Site-Specific Radiopharmaceuticals. Inorganic Chemistry, 2007, 46, 465-485.	4.0	134
59	Rapid preparation of [11C]flumazenil: captive solvent synthesis combined with purification by analytical sized columns. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 19-24.	1.0	24
60	Imaging of Brain Hypoxia in Permanent and Temporary Middle Cerebral Artery Occlusion in the Rat using 18F-Fluoromisonidazole and Positron Emission Tomography: A Pilot Study. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 679-689.	4.3	62
61	Intrinsic Activated Microglia Map to the Peri-infarct Zone in the Subacute Phase of Ischemic Stroke. Stroke, 2006, 37, 1749-1753.	2.0	163
62	Chemistry of Nitrogen-13 and Oxygen-15., 2005, , 119-140.		0
63	Flixotideâ"¢-pressurized metered-dose inhalers loaded with[18F]fluticasone propionate particles for drug deposition studies in humans with PET–formulation and analysis. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 55-70.	1.0	9
64	13th IIS(UK group) symposium. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 299-334.	1.0	3
65	Synthesis of [18F]Fluoromisonidazole (1-(2-Hydroxy-3-[18F]Fluoropropyl)-2-Nitroimidazole, [18F]FMISO). , 0, , 41-49.		1